Key facts
- This page summarizes Klaus W. Wagner's Form 4 filing for Boundless Bio, Inc. (BOLD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Mar 2024, 16:30.
Klaus W. Wagner - 27 Mar 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- BOLD
- Reported as of
- 27 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2024, 16:30:13 UTC
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jessica Oien, Attorney-in-Fact for Klaus Wagner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Klaus W. Wagner filed Form 4 for Boundless Bio, Inc. (BOLD) on 29 Mar 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BOLD
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +41,745
- Change %
- Price
- $0.000000
- Shares after
- 41,745
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,745
- Exercise price
- $16.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.